ClearAlpha Technologies LP Takes Position in Artivion, Inc. (NYSE:AORT)

ClearAlpha Technologies LP purchased a new position in Artivion, Inc. (NYSE:AORT) during the third quarter, Holdings Channel reports. The firm purchased 14,333 shares of the company’s stock, valued at approximately $382,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sio Capital Management LLC acquired a new stake in shares of Artivion during the 3rd quarter worth approximately $3,226,000. Walleye Capital LLC acquired a new stake in shares of Artivion in the 3rd quarter valued at $960,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after purchasing an additional 125,668 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Artivion by 543.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock worth $761,000 after buying an additional 24,130 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Artivion by 28.0% during the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after buying an additional 25,176 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Trading Up 1.6 %

Shares of NYSE AORT opened at $29.52 on Monday. The firm has a 50 day moving average price of $27.00 and a two-hundred day moving average price of $25.82. The stock has a market cap of $1.24 billion, a P/E ratio of -1,476.00 and a beta of 1.75. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Analysts Set New Price Targets

A number of research firms have issued reports on AORT. JMP Securities initiated coverage on Artivion in a research report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Artivion in a research note on Friday, September 27th. Oppenheimer increased their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus raised their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $31.00.

Insider Activity at Artivion

In other Artivion news, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 8.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 8.10% of the stock is currently owned by company insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.